Vernakalant (oral)

DRUG2 trials

Sponsors

Advanz Pharma

Conditions

Atrial Fibrillation

Phase 2

Study of RSD1235-SR for the Prevention of Atrial Fibrillation/Atrial Flutter Recurrence

CompletedNCT00267930

Advanz PharmaAtrial Fibrillation

Start: 2005-12-31End: 2006-08-31Updated: 2008-12-18

Vernakalant (Oral) Prevention of Atrial Fibrillation Recurrence Post-Conversion Study

CompletedNCT00526136

Advanz PharmaAtrial Fibrillation

Start: 2007-03-31End: 2008-07-31Updated: 2008-12-18

Related Papers

A randomized, placebo-controlled study of vernakalant (oral) for the prevention of atrial fibrillation recurrence after cardioversion.

2011-08-1428 citations